文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Cell-Based Therapeutic Strategies for Autoimmune Diseases.

作者信息

Quero Francisco B, Troncoso-Bravo Tays, Farías Mónica A, Kalergis Alexis M

机构信息

Millennium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.

Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

出版信息

Immunotargets Ther. 2025 Apr 28;14:501-514. doi: 10.2147/ITT.S513629. eCollection 2025.


DOI:10.2147/ITT.S513629
PMID:40322732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12047289/
Abstract

Currently, the management of autoimmune disorders still being a challenge in terms of safety, efficiency, and specificity. Cell-based therapeutic strategies have emerged as a novel approach for autoimmune disease treatment, employing different cell therapy platforms, including tolerogenic dendritic cells, regulatory T cells, conventional and regulatory chimeric antigen receptor-T cells, mesenchymal and hematopoietic stem cells, each with their biological features. Here, we discuss the different cell therapy platforms, their immunological mechanisms of action, their therapeutic potential and benefits in autoimmune diseases, and challenges related to their production, scaling up, risks, and patient safety.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d485/12047289/41bc2cb8ce0f/ITT-14-501-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d485/12047289/7b75e28045c6/ITT-14-501-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d485/12047289/41bc2cb8ce0f/ITT-14-501-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d485/12047289/7b75e28045c6/ITT-14-501-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d485/12047289/41bc2cb8ce0f/ITT-14-501-g0002.jpg

相似文献

[1]
Cell-Based Therapeutic Strategies for Autoimmune Diseases.

Immunotargets Ther. 2025-4-28

[2]
Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?

Front Immunol. 2020-11-26

[3]
Current advancements in cellular immunotherapy for autoimmune disease.

Semin Immunopathol. 2025-1-16

[4]
Tolerogenic Dendritic Cells and T-Regulatory Cells at the Clinical Trials Crossroad for the Treatment of Autoimmune Disease; Emphasis on Type 1 Diabetes Therapy.

Front Immunol. 2019-2-6

[5]
[Prerequisite and organisation of health-care pathways for Cell and Gene therapies, using Mesenchymal Stromal Cells (MSC) or Chimeric Antigen Receptor (CAR) T cells, in patients with autoimmune systemic diseases].

Bull Cancer. 2025-1

[6]
Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential.

Blood Rev. 2020-5

[7]
Chimeric antigen receptor-modified T-cell therapy: Recent updates and challenges in autoimmune diseases.

J Allergy Clin Immunol. 2025-3

[8]
Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.

J Neurol. 2024-10

[9]
Treg Enhancing Therapies to Treat Autoimmune Diseases.

Int J Mol Sci. 2020-9-23

[10]
Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders.

Mol Biol Rep. 2022-5

本文引用的文献

[1]
Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances.

Best Pract Res Clin Haematol. 2024-9

[2]
CAR-T cell therapy embarks on autoimmune disease.

Bone Marrow Transplant. 2025-1

[3]
Advancement in the development of mRNA-based vaccines for respiratory viruses.

Immunology. 2024-11

[4]
Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes.

NEJM Evid. 2024-7

[5]
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial.

Ann Rheum Dis. 2024-9-30

[6]
Dawn of CAR-T cell therapy in autoimmune diseases.

Chin Med J (Engl). 2024-5-20

[7]
Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus.

Nat Commun. 2024-3-27

[8]
Racial and Ethnic Differences in the Prevalence of Patients With Arthritis and Severe Joint Pain and Who Received Provider Counseling About Physical Activity for Arthritis Among Adults Aged 18 Years or Older-United States, 2019.

Arthritis Care Res (Hoboken). 2024-7

[9]
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.

N Engl J Med. 2024-2-22

[10]
Smith-specific regulatory T cells halt the progression of lupus nephritis.

Nat Commun. 2024-2-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索